nd-l02-s0201
Nucleic acidexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2013 (NCT01858935)
Timeline
Indications
Mechanism of action
- Collagen-binding protein 1ANTISENSE INHIBITOR
SERPINH1 antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- nd-l02-s0201
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03538301 | Phase 2 | Jun 18, 2018 | Nitto Denko Corporation |
| NCT03241264 | Phase 1 | Aug 28, 2016 | Bristol-Myers Squibb, Nitto Denko Corporation |
| NCT02227459 | Phase 1 | Oct 1, 2014 | Bristol-Myers Squibb, Texas Liver Institute, Tokuda Hospital |
| NCT01858935 | Phase 1 | May 1, 2013 | Bristol-Myers Squibb, IQVIA |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 3 | 3 | 1 | 2013 |
| Nitto Denko Corporation | For profit | 2 | 1 | 2 | 2016 |
| IQVIA | For profit | 1 | 0 | 1 | 2013 |
| Texas Liver Institute | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Tokuda Hospital | Academic/Hospital | 1 | 0 | 1 | 2014 |
5 organizations
Page 1 / 1